Results 51 to 60 of about 54,210 (294)

Post‐Translational Isoaspartate Promotes Amyloid Formation in β2‐Microglobulin

Angewandte Chemie, EarlyView.
Chemical synthesis of five β2‐microglobulin (β2m) variants reveals the structural impact of Asn deamidation. By introducing Asp or isoAsp at susceptible Asn‐Gly sequences, we demonstrate that isoAsp17 formation specifically accelerates amyloid fibril formation, highlighting its potential contribution to dialysis‐related amyloidosis.
Ryuji Kawakami, Toshiki Takei, Masatomo So, Toshifumi Takao, Yoshinori Taguchi, Hironobu Hojo   +5 more
wiley   +2 more sources

Localized AL amyloidosis

Terapevticheskii arkhiv
Localized light chain (AL) amyloidosis (amyloidoma) is a rare disease with unclear pathogenesis and undeveloped approaches to therapy. This article presents 3 clinical observations of localized AL amyloidosis with lesions of the respiratory tract, eyes, and soft tissues of the face.
Nelly A. Kashchavtseva, Irina G. Rekhtina, Alla M. Kovrigina, Tatyana P. Danilina, Larisa P. Mendeleeva   +4 more
openaire   +3 more sources

Improving management of AL amyloidosis

Annals of the Academy of Medicine, Singapore, 2023
In this issue of the Annals, Tan et al. on behalf of Singapore Myeloma Study Group presented the consensus guidelines on light chain (AL) amyloidosis.1 This is an encouraging effort as AL amyloidosis is a rare disease, with diagnostic and therapeutic challenges.
Yuh Shan, Lee, Jeffrey, Huang
openaire   +2 more sources

Epidemiology of AL amyloidosis: a real-world study using US claims data

Blood Advances, 2018
: Amyloid light-chain (AL) amyloidosis is a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to provide an up-to-date estimate of prevalence and incidence of AL amyloidosis in the United States ...
Tiffany P. Quock, Tingjian Yan, Eunice Chang, Spencer Guthrie, Michael S. Broder   +4 more
doaj   +1 more source

A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS; PULMONARY AL AMYLOIDOSIS

Hematology, Transfusion and Cell Therapy, 2022
Objective: Involvement of the lung is common in systemic AL amyloidosis in post-mortem series. However, the diagnosis is challenging. Histology is the gold standard but may result in bleeding. Consequently, diagnosis during life is rare.
Simge ERDEM, Nigar TAGHİYEVA, Kaan AKIN, Hilal KONYAOĞLU, Sevgi KALAYOĞLU BEŞIŞIK   +4 more
doaj   +1 more source

QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Advanced Science, EarlyView.
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V. Laurents, Mariano Carrión‐Vázquez   +8 more
wiley   +1 more source

Recurrent syncope and cardiac arrest in a patient with systemic light chain amyloidosis treated with bortezomib

Hematology Reports, 2016
About 10-15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope.
Navin Jaipaul, Alexander Pi, Zhiwei Zhang   +2 more
doaj   +1 more source

Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy

Case Reports in Gastrointestinal Medicine, 2021
Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo, Takehito Ito, Jun Nomura, Keigo Murakami, Shiho Kondo, Tomonori Satoh, Daisuke Fukushi, Yuki Yoshino, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kazuhiro Murakami, Junichi Kameoka, Kennichi Satoh   +15 more
doaj   +1 more source

Mechanisms underlying the initiation of cerebral betaamyloidosis and neurofibrillary tau pathology : new insights form transgenic mice [PDF]

, 2006
Numerous neurodegenerative disorders result from the aggregation of proteins that misfold and accumulate as fibrillar amyloid deposits in selectively vulnerable regions of the central nervous system.
Bolmont, Tristan
core   +1 more source

Carboranyl‐Curcuminoids for the Neutron Capture‐Based Treatment of Amyloid Aggregates in Alzheimer's Disease

Advanced Science, EarlyView.
The 10B‐enriched monocarbonyl analog of curcumin (BMAC) 10B‐9 enables site‐specific Boron Neutron Capture Therapy (BNCT) on amyloid‐β (Aβ) fibrils. Neutron irradiation induces histidine oxidation and fibril destabilization, as revealed by 1H‐NMR and FESEM analyses.
Sebastiano Micocci, Stefano Parisotto, Diego Alberti, Alberto Lanfranco, Valeria Bitonto, Polyssena Renzi, Martina Salmi, Andrea Magnani, Federica Dal Bello, Katiuscia Pagano, Laura Ragona, Nicoletta Protti, Annamaria Deagostino, Simonetta Geninatti Crich   +13 more
wiley   +1 more source